Business
Senseonics Announces Positive Coverage Decision for Eversense CGM from Several Blue Cross Blue Shield Plans
--Blue Cross and Blue Shield coverage decisions add nearly 10 million covered lives for Eversense CGM-- GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics
About this update from Senseonics Holdings, Inc.
[{"type":"text","content":"\n--Blue Cross and Blue Shield coverage decisions add nearly 10 million covered lives for Eversense CGM--\n\n GERMANTOWN, Md.--(BUSINESS WIRE)--\nSenseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that three more Blue Cross Blue Shield plans are now providing coverage for the Eversense® CGM System, effective immediately. These recent coverage decisions add to the growing number of payers who are writing Eversense into their CGM coverage policies, as well as paying for the healthcare provider’s time for the in-office sensor placement.\n\n\nBlue Cross and Blue Shield of Arizona has added coverage for Eversense which expands access to approximately 1.5 million Arizona residents. CareFirst Blue Cross and Blue Shield offers health plans and administrative services to approximately 3.3 million individuals and employers in Maryland, the District of Columbia, and Northern Virginia and has expanded coverage for Eversense. Independence Blue Cross and AmeriHealth have also opened the door to coverage for Eversense as they serve approximately 4.8 million people in Pennsylvania and surrounding markets.\n\n\n“We are excited to see the continued progress on the expansion of coverage for Eversense as the payer community recognizes the value Eversense provides for patients using insulin to manage their diabetes and the need for more CGM options,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. “Improved glucose control for patients with diabetes has always been a focal point for health care professionals, but now more than ever we are seeing the impacts of poor glucose control in patients who contract COVID-19. Given this new environment, it is becoming even more vital for patients to have an array of options to better manage their diabetes. Eversense offers patients a new choice in the CGM class that delivers outstanding accuracy and patient experience, and an opportunity to achieve improved health outcomes.”\n\n\nThe Eversense CGM System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends and alerts. In ...